6. REFERENCES:

1. Shankar M.B., Mehta F.A., Bhatt K.K., Mehta R.S., and Geetha M. (2008), An Introduction To Analytical Method Development For Pharmaceutical Formulations,*Indian Journal of pharmaceutical sciences,* **65(2)**, 167-170.
2. Lattanzi L., Dell'Osso L., Cassano P., Pini S., Rucci P., Houck P., Gemignani A., Battistini G., Bassi A., Abelli M., Cassano G. (2002), "Pramipexole in treatment-resistant depression: a 16-week naturalistic study.", *Bipolar Disord.* **4 (5)**, 307–314.
3. Holman A., Myers R. (2005), "A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications.", *Arthritis Rheum* , **52 (8)**, 2495–2505.
4. Sweetman S., editor. Martindale: The Complete Drug Reference, 35th ed. London, Pharmaceutical press 2007, 739-756.
5. Ramirez A., Wong S., Menniti F.(2003), Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms, *Eur. J. Pharmacol* , **475 (1) ,** 29-35.
6. Schneider C., Mierau J. (1987), "Dopamine autoreceptor agonists: resolution and pharmacological activity of 2,6-diaminotetrahydrobenzothiazole and an aminothiazole analog of apomorphine". *Journal of Medicinal Chemistry* **30 (3) ,** 494–498.
7. The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human use: Harmonised Tripartite Guideline on Stability Testing of New Drug substances and Products, Q1A (R2), **(2006)**.
8. Parmar D., jadhav S.,(2008) The concept of personal drugs in the undergraduate pharmacology practical curriculum, *Indian J Pharmacol*, **40 (6)**, 281-282.
9. Biljana J., Mirjana M., Darko I., Anjelija M. (2007), Experimental Design in Chromatographic Analysis of Pramipexole and Its Impurities, *Acta Chim. Slov*., **54**, 49–54.
10. Panditrao V., Sarkate J., Sangshetti P., Wakte S.and Shinde D. (2011), Stability-Indicating HPLC Determination of Pramipexole dihydrochloride in Bulk Drug and Pharmaceutical Dosage Form, *J. Braz. Chem. Soc*., **22 (7)**, 1253-1258.

11. Manjunath S., Middi S. and Chouhan V. (2011), A Novel Spectrophotometric Estimation of Pramipexole in Bulk Drug and Formulations, *RGUHS Journal of Pharmaceutical Sciences, RJPS*, **1 (2)**, 107-110.
12. Humaira S., Dey A., Appala S., Sanaullah S. (2010), Gradient Ultra Fast Liquid Chromatographic Analysis of Pramipexole and its Application to Drug Quality control, *Scholars Research Library*, **2 (4),** 315-325.
13. Wakode R. and Bajaj A. (2010), Once a day osmotic drug delivery system for highly water soluble Pramipexole, *J. Chem. Pharm. Res*., **2 (2),** 136-146.
14. Narendra Kumar R., Nageswara Rao G., Naidu P. Y. (2011), Stability indicating RP-LC method for determination of Pramipexole in bulk and pharmaceutical dosage forms, *Pelagia Research Library,Der Pharmacia Sinica*, **2 (4),** 125-135.
15. Vinodhini C., Sravani M., Bhanuprakash M., Mantena.s., Imran M., Omer M., Osman A., Chitra K., Reddy C. (2011), Method Development and Validation of Pramipexole Dihydrochloride in Tablet Dosage Form by UV and Visible Spectrophotometric Methods, **2 (2)**,680-686.
16. Gurupadayya B., Vishwajith V. and Srujana N. (2009), Spectrophotometric Methods for the Estimation of Pramipexole Dihydrochloride in Pharmaceutical Formulations, *World Journal of Chemistry* ,**4 (2)**, 157-160.
17. Wakode R. and Bajaj A. (2010), Formulation and in vivo evaluation of once a day push-pull osmotic tablets, International *Journal of Pharma and Bio Sciences*,**1 (4)**,44-56.
18. Malenovi A., Jani S., Biljana V., Ivanovi A., Mirjana D., (2011)Validation of a Column Liquid Chromatographic Method for the Analysis of Pramipexole and Its Five Impurities , *Journal of AOAC International*, **93 (4)**,1102-1112.
19. F.D.A guidance for industry. Draft stability testing of drug substance and drug product, (1998).
20. Investigation of bioavailability and Bioequivalence (1999): The rule governing medicinal products in European community., **3 (2)** , 149-169.
21. The International Conference on Harmonization of Technical requirements for Registration of Pharmaceuticals for Human Use .Q3C, Impurities in New Drug Products, July 1997.

22. The International Conference on Harmonization of Technical requirements for Registration of Pharmaceuticals for Human Use .Q3B (R) Impurities in New Drug Products, October 1999.
23. The International Conference on Harmonization of Technical requirements for validation of analytical procedures .Q2 (R1) validation of analytical procedures in New Drug Products, June 1995.
24. The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human use: Harmonised Tripartite Guideline on Impurities in New Drug Substances Q3A (R2), **(2006)**.
25. The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human use: Harmonised Tripartite Guideline on Q6A, Specification: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, (**2006)**.
26. ICH Harmonized Tripartite Guideline, ICH Q2A, Text on Validation of Analytical procedures, June **(1995)**.
27. ICH Harmonized Tripartite Guideline, ICH Q2B, Validation of Analytical procedures: Methodology,June **(1997)**.
28. Ahuja S., Impurities evaluation in pharmaceuticals, ed. Marcel Deckker, NY, **(1998)**.
29. Martindale, The complete drug reference, thirty – third edition, Edn by Sean C Sweetman, Pharmaceutical Press.
30. Sethi P.D., High Performance liquid Chromatography – Quantitative Analysis of Pharmaceutical formulation, CPS Publishers & Distributors, (**2001)**.
31. Smith R. J., Webb M. L., Analysis of Drug Impurities, Blackwell publishing, (**2007)**.
32. Ahuja S., Rasmussen H., HPLC method development for pharmaceuticals, Volume 8 of Separation Science and technology, (**2007)**.
33. Reviewer Guidance: Validation of chromatographic Methods, Centre for Drug and Research .U.S. Government Printing office, Washington DC, **(1994)**.
34. Meizer P.C., Zund R.E., Statistical Methods in Analytical chemistry .Edn John Wiley & Sons, Inc, USA, **(1999)**.
35. Devlin D., Text book of biochemistry With clinical correlations, Edn .Hoboken N.J ,Wiley Liss-John Wiley and Sons , 6th Edition ,(**2006**).

Signature of the Candidate **Signature of the Research Supervisor**

(Motiram H. Patil) **(Manoj D. Rokade)**